Depletion of Paneth cells is associated with decreased portal hypertension and angiogenesis after partial portal vein ligation in mice.
EASL LiverTree™, Mohsin Hassan, 207335
A functional metagenomics investigation of cirrhotic patients highlights distinctive microbiota features involved in bacterial translocation, systemic inflammation and hepatic encephalopathy
EASL LiverTree™, Vincenza Di Gregorio, 207336
The pathogenic role of Stat2 in inflammation is independent of canonical interferon signaling and is mediated by TNFa.    
EASL LiverTree™, William Alazawi, 207351
Step-wise strategy for Chinese Budd-Chiari syndrome patients: long-term outcome of a large scaleprospective observational cohort
EASL LiverTree™, Guohong Han, 207367
Hepatic outcomes from childhood intestinal failure: a meta-analysis of 8223 patients
EASL LiverTree™, Aureliane Pierret, 207368
Comparison between Room-Temperature Susceptometry and MRI with respect to the cell-specific detection of liver iron
EASL LiverTree™, Johannes Mueller, 207370
Alpha1-antitrypsin augmentation therapy is associated with an improvement in liver-related parameters in patientes with severe alpha1-antitrypsin-deficiency
EASL LiverTree™, Carolin Victoria Heimes, 207371
Transcatheter recanalization with angioplasty and/or stenting: a novel, minimally-invasive treatment option for children with chronic portal vein thrombosis with cavernous transformation
EASL LiverTree™, Tamir Miloh, 207384
Clinical response after laparoscopic fenestration of large simple hepatic cysts: a systematic review
EASL LiverTree™, Lucas Bernts, 207385
Pertinence of liver stiffness measurement inpatients with Wilson's disease for assessment of initial fibrosis and treatmentfollow-up
EASL LiverTree™, Rodolphe Sobesky, 207386
Clinicalpresentation and outcome of Wilson’s disease patients in a monocentric cohort ofliver reference center
EASL LiverTree™, Rodolphe Sobesky, 207387
Controlled Attenuation Parameter reflects intrahepatic fat content in patients with compensated advanced chronic liver disease
EASL LiverTree™, Rosangela Piccinni, 207403
Usefulness of liver stiffness measurement by transient elastography (TE) for predicting complications in patients with alcoholic liver disease
EASL LiverTree™, Ana Gomez, 207405
Evaluation of Multiparametric MRI in comparison with MR Elastography in patients evaluated for chronic liver disease
EASL LiverTree™, Stephen Bravo, 207406
Glomerular filtration rate evaluation in patients with cirrhosis, which equation shall be used in clinical daily practice?
EASL LiverTree™, Sofia Monteiro, 207407
Evolving diagnostic pathways in liver disease: using quantitative magnetic resonance imaging to distinguish parenchymal and biliary disease.
EASL LiverTree™, Katherine Arndtz, 207422
Non invasive diagnostic approach for screening and grading of portal hypertension in patients with advanced liver disease.
EASL LiverTree™, Sergii Kozlov, 207423
Circulating micro-ARNs as biomarkers of alcohol liver disease and hepatocellular carcinoma
EASL LiverTree™, Charles-Antoine PAPILLON, 207424
The effectiveness of a pharmacological intervention for defatting of primary human hepatocytes and its effect on other cell types ofthe liver: a precursor in-vitro study to the defatting of steatotic humanlivers using normothermic machine perfusion
EASL LiverTree™, Yuri Boteon, 207442
Establishing a porcine model of small for size syndrome following liver resection
EASL LiverTree™, Mohammad Golriz, 207444
Induction of beta-catenin in embryonic stem cell-derived dendritic cells alleviates liver damage in mouse liver inflammatory injury
EASL LiverTree™, Bibo Ke, 207445
Sealant pathology
EASL LiverTree™, Omid Ghamar Nejad, 207446
Sorafenib increases the percentage and cytotoxicity of circulating NK cells in hepatocellular carcinoma patients
EASL LiverTree™, Guohong Han, 207459
Rapamycin and Zoledronic Acid strongly inhibit growth of advanced murine hepatocellular carcinoma via activation of innate and adaptive immunity
EASL LiverTree™, Muhammad Ashfaq Khan, 207460
Insulin receptor isoform A is a new player in the progression of hepatocellular carcinoma
EASL LiverTree™, Eva Benabou, 207462
Defective DNAM-1 mediated cytotoxicity in NK cells infiltrating hepatocellular carcinoma
EASL LiverTree™, Barbara Oliviero, 207463
Peribiliary glands and biliary tree stem cells are involved in the pathogenesis of cholangiocarcinoma arising in patients affected by primary sclerosing cholangitis
EASL LiverTree™, Diletta Overi, 207479
EASL LiverTree™, Wolfgang Mikulits, 207480
Mitochondrial VDAC1 based peptide as a new therapeutic agent for hepatocellular carcinoma 
The role of Lysyl oxidase in tumor microenvironment of primary liver cancer
EASL LiverTree™, Monika Lewinska, 207482
Application of patient-derived liver cancer cells for personalized treatment approach: from phenotypic characterization to therapeutic target identification 
EASL LiverTree™, Darko Castven, 207496
High miR-224 expression in cholangiocarcinoma may predict survival 
EASL LiverTree™, Tímea Szekerczés, 207498
Do extracellular vesicles secreted from senescent hepatic stellate cells promote or suppress cancer development?
EASL LiverTree™, Yuri Miyazoe, 207499
Sofosbuvir directly promotes the clonogenic capability of human hepatocellular cancer cells 
EASL LiverTree™, Jiaye Liu, 207514
Protective effect  of statins in cirrhosis might be dependent on common genetic risk variants
EASL LiverTree™, Matthias Reichert, 207516
Determinants of clinical efficacy of empirical antibiotic treatment in patients with cirrhosis and bacterial infections: Results from the ICA Global study
EASL LiverTree™, Rakhi Maiwall, 207517
The mechanism of irreversibility of late stage cirrhosis
EASL LiverTree™, Ian R. Wanless, 207518
Characterization of systemic inflammatory response in hepatorenal syndrome in cirrhosis. A major role for il-6, TNF-alpha, and VCAM
EASL LiverTree™, Cristina Sole Marti, 207532
Skeletal Muscle Index (SMI) Indicates Mortality Risk More Accurately than Psoas Muscle Index (PMI) in Patients with Cirrhosis. From The FLEXIT Consortium.
EASL LiverTree™, Aldo J. Montano-Loza, 207533
Loss of Subcutaneous Adipose Tissue Associates with Higher Mortality Risk in Patients with Cirrhosis
EASL LiverTree™, Aldo J. Montano-Loza, 207534
Assessment of biventricular function in patients with decompensated cirrhosis and hepatopulmonary syndrome
EASL LiverTree™, Stergios Soulaidopoulos, 207535
The impact of hepatic steatosis on portal hypertension
EASL LiverTree™, Bernhard Scheiner, 207548
Controlled attenuation parameter (CAP) does not predict hepatic decompensation in patients with advanced chronic liver disease
EASL LiverTree™, Bernhard Scheiner, 207549
Thromboelastography guided blood product transfusion in cirrhosis patients with acute variceal bleeding: a Randomized Controlled Trial
EASL LiverTree™, Gyanranjan Rout, 207550
EASL LiverTree™, Luis Téllez, 207564
EASL LiverTree™, Luis Téllez, 207565
Distinct MELD Trajectories in Liver Transplant Candidates with Hepatitis C and NASH
EASL LiverTree™, Allison Kwong, 207566
Effect of vardenafil on portal hemodynamics in patients with mild and moderate liver dysfunction: a randomized, placebo-controlled trial
EASL LiverTree™, Rafael Paternostro, 207568
Clinical, paraclinical and MR-spectroscopy profile in cirrhotic and non-cirrhotic portal hypertension patients with minimal hepatic encephalopathy
EASL LiverTree™, Bertrand Hermann, 207584
Multimodal approach including MR-spectroscopy for the diagnosis of minimal hepatic encephalopathy
EASL LiverTree™, Bertrand Hermann, 207585
EASL LiverTree™, Alberto Amador, 207586
The time trend of hospital admissions, inpatient mortality rate, and hospital cost of hospitalizations associated with cirrhosis in the United States: an analysis on the National Inpatient Sample
EASL LiverTree™, Donghak Jeong, 207601
Validation and modification of Baveno criteria to rule out high- risk varices in patients with compensated cirrhosis
EASL LiverTree™, Varun Ravindra Tadkalkar, 207602
Outcomes of intrahepatic porto-systemic shunt in the treatment of portal vein thrombosis: a systematic review and meta-analysis
EASL LiverTree™, Susana Rodrigues, 207603
Clinically significant portal hypertension in chronic liver disease: always cirrhosis?
EASL LiverTree™, Susana Rodrigues, 207604
A simple patient-reported instrument can predict development of overt hepatic encephalopathy
EASL LiverTree™, Mette Munk Lauridsen, 207618
The continuous reaction time test for minimal hepatic encephalopathy validated by a randomized controlled multi-modal intervention
EASL LiverTree™, Mette Munk Lauridsen, 207619
Transjugular Intrahepatic Portosystemic Shunt Versus Beta-blocker and/or Endotherapy  for Prevention of Variceal Rebleeding in adults with EHPVO
EASL LiverTree™, Guohong Han, 207620
A prospective evaluation of symptom burden,opioid risk in cirrhosis patients
EASL LiverTree™, Mina Niazi, 207622
A study evaluating outcomes of cirrhotic patients managed in a dedicated liver cirrhosis clinic and factors influencing survival.
EASL LiverTree™, David Kockerling, 207635
Frialty is an independent predictive factor of hospital admissions and falls in patients with cirrhosis
EASL LiverTree™, Eva Roman, 207636
Cardiac assessment in children with chronic liver disease: cholestatic and non-cholestatic 
EASL LiverTree™, Tawhida Abdel Ghaffar, 207637
Non-invasive predictors of varices in non-cirrhotic portal hypertension
EASL LiverTree™, Morven Cunningham, 207638
Poor outcome of acute hepatitis E in liver cirrhosis and transplant recipients
EASL LiverTree™, Maria Buti, 207654
Incidence of hepatitis E infection in renal transplant patients in The Netherlands
EASL LiverTree™, robin erken, 207657
Potential contribution of more sensitive hepatitis B surface antigen assays to detect and monitor hepatitis B infection
EASL LiverTree™, Charlotte Pronier, 207673
Compare HBsAg retention in the endoplasmic reticulum (ER) and the ER stress between the cells transfected or infected by the wild type and pre-S HBV mutants using in vitro transfection and in vivo infection of FRG mice
EASL LiverTree™, Jenny Yuh-Jin Liang, 207674
HBV Peptide Array Demonstrates Candidate Mechanisms of CRV431 Anti-HBV Activity
EASL LiverTree™, Robert Foster, 207675
Assessing the in vitro anti-HBV activity of combinations including CRV431,  TXL, and  prototype capsid assembly modulators
EASL LiverTree™, Robert Foster, 207676
Reduction of serum infectivity of Hepatitis Delta virus-infected patients treated with Myrcludex B: An in vitro assay to determine infectious units
EASL LiverTree™, Katrin Schöneweis, 207689
The protein complex structural maintenance of chromosomes reappears after interferon alpha treatment in hepatitis B virus infected humanized mice but its presence does not hinder viral rebound
EASL LiverTree™, Maura Dandri, 207690
Hepatitis B virus escapes non-canonical CTL effector function
EASL LiverTree™, Percy A. Knolle and Dirk Wohlleber, 207691
HBsAg transcomplementation of defective HBV genomes in HBeAg negative chronic HBV infected patients 
EASL LiverTree™, Kai-Henrik Peiffer, 207692
Statins suppress hepatitis B virus replication and reduce hepatoma cell viability by interfering with Rho-GTPases
EASL LiverTree™, Maarten van de Klundert, 207708
Understanding the multiphasic viral kinetics of cute HBV infection observed in humanized uPA/SCID mice using an agent-based modeling approach
EASL LiverTree™, Harel Dahari, 207709
Understanding HDV and HBV dynamics during acute co-infection in humanized uPA/SCID chimeric mice using an agent-based modeling appraoch
EASL LiverTree™, Harel Dahari, 207710
Induction of specific CD4+ T cell helper responses following recombinant ChAd3/MVA vaccination against HCV
EASL LiverTree™, Ilaria Esposito, 207727
Induction of liver sinusoidal endothelial cells immune activation by HBeAg during HBV infection
EASL LiverTree™, Jia Liu, 207728
Regulation of antiviral CD8 T cell response by MMP mediated soluble CD100 releasing in HBV infection
EASL LiverTree™, Jia Liu, 207729
EP2 associated with the inflammatory storm in HBV related acute-on-chronic liver failure
EASL LiverTree™, Yunyun Wang, 207746
Characterization of theHEV-specific CD8+ T-cell response in acute and chronic Hepatitis E virus infection
EASL LiverTree™, Janine Kemming, 207748
Bayesian sparse regression modelling more accurately predicts mortality risk than commonly used prognostic scoring systems in patients with severe alcoholic hepatitis
EASL LiverTree™, Stephen Atkinson, 207763
Insufficient diagnostic accuracy of general practitioners and routine liver function tests lead to high risk of under-referrals of patients with alcohol induced advanced liver fibrosis
EASL LiverTree™, Thor Lars Hansen, 207764
Delineating Complement Activation Molecular Patterns in Patients with Alcoholic Hepatitis
EASL LiverTree™, Rebecca McCullough, 207765
Presence of IgA isotype F-actin is frequent in patients with cirrhosis and consitutes the risk of progressive disease course
EASL LiverTree™, Boglárka Balogh, 207766
Maternal dietary patterns and the risk of large-for-gestational age births
EASL LiverTree™, Satomi Minato, 207781
Impact of short term weight loss (very low calorie diet vs  bariatric surgery) on hepatic insulin resistance and plasma lipidomic profile
EASL LiverTree™, Chiara Barbieri, 207782
Substantial healthcare utilization (HCU) and costs among non-alcoholic steatohepatitis (NASH) patients with comorbid diabetes mellitus (DM): Real-world analysis of 2007-2015 US Medicare data
EASL LiverTree™, Stuart Gordon, 207783
Prediction of decompensation events in NASH cirrhosis patients
EASL LiverTree™, Roberta Forlano, 207784
Association of Nonalcoholic Fatty Liver Disease with Changes in Left Ventricular Structure and Function: The Coronary Artery Risk Development in Young Adults (CARDIA) Study 
EASL LiverTree™, Lisa VanWagner, 207797
Investigating the Relationship Between Rare Genetic Variants and Advanced Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease
EASL LiverTree™, Julia Wattacheril, 207798
Mixed hepatic iron deposition but not serum ferritin is associated with the presence of nonalcoholic steatohepatitis (NASH)
EASL LiverTree™, Elena Buzzetti, 207800
EASL LiverTree™, Giampaolo Bianchi, 207801
Influence of non-alcoholic fatty liver disease on cardiovascular risk in patients with stable coronary heart disease
EASL LiverTree™, Iryna Vakalyuk, 207815
Metabolically unhealthy status impacts on the risk of significant liver injury in biopsy-proven NAFLD patients beyond obesity
EASL LiverTree™, Javier Ampuero, 207816
Hepatitis C Virus Eradication by Direct Antiviral Agents Improves Carotid Atherosclerosis in Patienst with Advanced Fibrosis/Compensated Cirrhosis
EASL LiverTree™, Salvatore Petta, 207818
Sex hormone binding globulin levels are increased in HIV-infected men and are independently associated with lower odds of nonalcoholic fatty liver disease regardless of HIV serostatus
EASL LiverTree™, Jennifer Price, 207832
The Conundrum of Cryptogenic Liver Disease with Advanced Fibrosis: Poor Clinical Outcomes without Treatment Options
EASL LiverTree™, Zobair Younossi, 207833
The Worldwide Prevalence of Non-alcoholic Steatohepatitis (NASH) in Patients with Type 2 Diabetes Mellitus (DM)
EASL LiverTree™, Zobair Younossi, 207834
Moderate Alcohol Consumption Protects Against Fatty Liver in Males
EASL LiverTree™, Takemi Akahane, 207835

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.

Save Settings